UNICREDIT BANK/CALL/ELI LILLY & CO/700/0.1/18.12.24 | Real-time BOERSE MUENCHEN 01:10:03 13/06/2024 pm IST | ||
| 18.49 EUR | +1.37% |
|
| Current month | +25.71% | ||
| 1 month | +64.77% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 13/24/13 | 18.49 | +1.37% |
| 12/24/12 | 18.24 | -1.30% |
| 11/24/11 | 18.48 | -0.32% |
| 10/24/10 | 18.54 | +7.42% |
| 07/24/07 | 17.26 | +8.49% |
Real-time BOERSE MUENCHEN
Last update June 13, 2024 at 01:10 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HC7N7B |
| ISIN | DE000HC7N7B6 |
| Date issued | 23/06/2023 |
| Strike | 700 $ |
| Maturity | 18/12/2024 (189 Days) |
| Parity | 10 : 1 |
| Emission price | 1.18 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.07 € |
|---|---|
| Lowest since issue | 0.58 € |
| Spread | 0.18 € |
| Spread % | 0.97% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
867.3
USD
Average target price
855.2
USD
Spread / Average Target
-1.40%
- Stock Market
- Warrants
- Warrant
